Opioids in chronic non-cancer pain

Bibliography

• Model policy for the use of controlled substances for the treatment of pain. Federation of State Medical Boards of the United States, Dallas; 2004
   Google Scholar
• Cousins MJ, Brennan F, Carr DB. Pain relief: a universal human right. Pain 2004;112(1-2):1-4
   PubMedGoogle Scholar
• Breivik H, Collett B, Ventafridda V, Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 2006;10(4):287-333
   PubMed Web of Science ®Google Scholar
• Eriksen J, Jensen MK, Sjogren P, Epidemiology of chronic non-malignant pain in Denmark. Pain 2003;106(3):221-8
   PubMedGoogle Scholar
• Parsells Kelly J, Cook SF, Kaufman DW, Prevalence and characteristics of opioid use in the US adult population. Pain 2008;138(3):507-13
   PubMedGoogle Scholar
• Kalso E, Allan L, Dellemijn PL, Recommendations for using opioids in chronic non-cancer pain. Eur J Pain 2003;7(5):381-6
   PubMedGoogle Scholar
• Chou R, Fanciullo GJ, Fine PG, Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009;10(2):113-30
   PubMedGoogle Scholar
• Trescot AM, Helm S, Hansen H, Opioids in the management of chronic non-cancer pain: an update of American Society of the Interventional Pain Physicians' (ASIPP) Guidelines. Pain Physician 2008;11(2 Suppl):S5-62
   Google Scholar
• Recommendation for the appropriate use of opioids for persistent noncancer pain. A consensus statement prepared on behalf of the pain society, the Royal College of Anaesthetists, the Royal College of General Practitioners and the Royal College of Psychiatrists. The Pain Society, London; 2004
   Google Scholar
• Eriksen J, Sjogren P, Bruera E, Critical issues on opioids in chronic non-cancer pain: an epidemiological study. Pain 2006;125(1-2):172-9
   PubMedGoogle Scholar
• Sullivan MD, Edlund MJ, Steffick D, Unutzer J. Regular use of prescribed opioids: association with common psychiatric disorders. Pain 2005;119(1-3):95-103
   PubMedGoogle Scholar
• United States of America v. Ronald A. McIver. 2005:4-745
   Google Scholar
• Breivik H. Opioids in chronic non-cancer pain, indications and controversies. Eur J Pain 2005;9(2):127-30
   PubMedGoogle Scholar
• Dworkin RH, Turk DC, Wyrwich KW, Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008;9(2):105-21
   PubMed Web of Science ®Google Scholar
• Trescot AM, Glaser SE, Hansen H, Effectiveness of opioids in the treatment of chronic non-cancer pain. Pain Physician 2008;11(2 Suppl):S181-200
   Google Scholar
• Ballantyne JC. Opioid analgesia: perspectives on right use and utility. Pain Physician 2007;10(3):479-91
   PubMedGoogle Scholar
• Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E. Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ 2006;174(11):1589-94
   PubMedGoogle Scholar
• Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain 2004;112(3):372-80
   PubMedGoogle Scholar
• Martell BA, O'Connor PG, Kerns RD, Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction. Ann Intern Med 2007;146(2):116-27
   PubMedGoogle Scholar
• Deshpande A, Furlan A, Mailis-Gagnon A, Opioids for chronic low-back pain. Cochrane Database Syst Rev 2007;(3):CD004959
   Google Scholar
• Cepeda MS, Camargo F, Zea C, Valencia L. Tramadol for osteoarthritis: a systematic review and metaanalysis. J Rheumatol 2007;34(3):543-55
   PubMedGoogle Scholar
• Eisenberg E, McNicol E, Carr DB. Opioids for neuropathic pain. Cochrane Database Syst Rev 2006;3:CD006146
   Google Scholar
• Noble M, Treadwell JR, Tregear SJ, Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev 2010;(1):CD006605
   Google Scholar
• Milligan K, Lanteri-Minet M, Borchert K, Evaluation of long-term efficacy and safety of transdermal fentanyl in the treatment of chronic noncancer pain. J Pain 2001;2(4):197-204
   PubMedGoogle Scholar
• Rauck RL, Bookbinder SA, Bunker TR, A randomized, open-label, multicenter trial comparing once-a-day AVINZA (morphine sulfate extended-release capsules) versus twice-a-day OxyContin (oxycodone hydrochloride controlled-release tablets) for the treatment of chronic, moderate to severe low back pain: improved physical functioning in the ACTION trial. J Opioid Manag 2007;3(1):35-43
   PubMedGoogle Scholar
• Jensen MK, Thomsen AB, Hojsted J. 10-year follow-up of chronic non-malignant pain patients: opioid use, health related quality of life and health care utilization. Eur J Pain 2006;10(5):423-33
   PubMedGoogle Scholar
• Caldwell JR, Rapoport RJ, Davis JC, Efficacy and safety of a once-daily morphine formulation in chronic, moderate-to-severe osteoarthritis pain: results from a randomized, placebo-controlled, double-blind trial and an open-label extension trial. J Pain Symptom Manage 2002;23(4):278-91
   PubMedGoogle Scholar
• Adams EH, Chwiecko P, Ace-Wagoner Y, A study of AVINZA (morphine sulfate extended-release capsules) for chronic moderate-to-severe noncancer pain conducted under real-world treatment conditions–the ACCPT Study. Pain Pract 2006;6(4):254-64
   PubMedGoogle Scholar
• Allan L, Richarz U, Simpson K, Slappendel R. Transdermal fentanyl versus sustained release oral morphine in strong-opioid naive patients with chronic low back pain. Spine 2005;30(22):2484-90
   PubMedGoogle Scholar
• Fishbain DA, Cutler RB, Rosomoff HL, Rosomoff RS. Are opioid-dependent/tolerant patients impaired in driving-related skills? A structured evidence-based review. J Pain Symptom Manage 2003;25(6):559-77
   PubMedGoogle Scholar
• Caudill-Slosberg MA, Schwartz LM, Woloshin S. Office visits and analgesic prescriptions for musculoskeletal pain in US: 1980 vs. 2000. Pain 2004;109(3):514-19
   PubMedGoogle Scholar
• Vogt MT, Kwoh CK, Cope DK, Analgesic usage for low back pain: impact on health care costs and service use. Spine 2005;30(9):1075-81
   PubMedGoogle Scholar
• Webster BS, Verma SK, Gatchel RJ. Relationship between early opioid prescribing for acute occupational low back pain and disability duration, medical costs, subsequent surgery and late opioid use. Spine 2007;32(19):2127-32
   PubMedGoogle Scholar
• Zacny J, Bigelow G, Compton P, College on problems of drug dependence taskforce on prescription opioid non-medical use and abuse: position statement. Drug Alcohol Depend 2003;69(3):215-32
   PubMedGoogle Scholar
• Mahmud MA, Webster BS, Courtney TK, Clinical management and the duration of disability for work-related low back pain. J Occup Environ Med 2000;42(12):1178-87
   PubMedGoogle Scholar
• Collett BJ. Opioid tolerance: the clinical perspective. Br J Anaesth 1998;81(1):58-68
   PubMedGoogle Scholar
• Sjogren P, Thunedborg LP, Christrup L, Is development of hyperalgesia, allodynia and myoclonus related to morphine metabolism during long-term administration? Six case histories. Acta Anaesthesiol Scand 1998;42(9):1070-5
   PubMedGoogle Scholar
• Angst MS, Clark JD. Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology 2006;104(3):570-87
   PubMedGoogle Scholar
• Athanasos P, Smith CS, White JM, Methadone maintenance patients are cross-tolerant to the antinociceptive effects of very high plasma morphine concentrations. Pain 2006;120(3):267-75
   PubMedGoogle Scholar
• Doverty M, White JM, Somogyi AA, Hyperalgesic responses in methadone maintenance patients. Pain 2001;90(1-2):91-6
   PubMedGoogle Scholar
• Joly V, Richebe P, Guignard B, Remifentanil-induced postoperative hyperalgesia and its prevention with small-dose ketamine. Anesthesiology 2005;103(1):147-55
   PubMed Web of Science ®Google Scholar
• Chu LF, Clark DJ, Angst MS. Opioid tolerance and hyperalgesia in chronic pain patients after one month of oral morphine therapy: a preliminary prospective study. J Pain 2006;7(1):43-8
   PubMed Web of Science ®Google Scholar
• Mao J, Sung B, Ji RR, Lim G. Chronic morphine induces downregulation of spinal glutamate transporters: implications in morphine tolerance and abnormal pain sensitivity. J Neurosci 2002;22(18):8312-23
   PubMedGoogle Scholar
• Sjogren P, Jensen NH, Jensen TS. Disappearance of morphine-induced hyperalgesia after discontinuing or substituting morphine with other opioid agonists. Pain 1994;59(2):313-16
   PubMedGoogle Scholar
• Compton P, Charuvastra VC, Ling W. Pain intolerance in opioid-maintained former opiate addicts: effect of long-acting maintenance agent. Drug Alcohol Depend 2001;63(2):139-46
   PubMedGoogle Scholar
• Raehal KM, Bohn LM. Mu opioid receptor regulation and opiate responsiveness. AAPS J 2005;7(3):E587-91
   Google Scholar
• Wang HY, Friedman E, Olmstead MC, Burns LH. Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gbetagamma signaling. Neuroscience 2005;135(1):247-61
   PubMedGoogle Scholar
• Yoburn BC, Gomes BA, Rajashekara V, Role of G(i)alpha2-protein in opioid tolerance and mu-opioid receptor downregulation in vivo. Synapse 2003;47(2):109-16
   PubMedGoogle Scholar
• Noble F, Cox BM. Differential desensitization of mu- and delta- opioid receptors in selected neural pathways following chronic morphine treatment. Br J Pharmacol 1996;117(1):161-9
   PubMedGoogle Scholar
• Sim-Selley LJ, Selley DE, Vogt LJ, Chronic heroin self-administration desensitizes mu opioid receptor-activated G-proteins in specific regions of rat brain. J Neurosci 2000;20(12):4555-62
   PubMedGoogle Scholar
• Bohn LM, Lefkowitz RJ, Caron MG. Differential mechanisms of morphine antinociceptive tolerance revealed in (beta)arrestin-2 knock-out mice. J Neurosci 2002;22(23):10494-500
   PubMedGoogle Scholar
• Yabaluri N, Medzihradsky F. Down-regulation of mu-opioid receptor by full but not partial agonists is independent of G protein coupling. Mol Pharmacol 1997;52(5):896-902
   PubMedGoogle Scholar
• Saeki S, Yaksh TL. Suppression of nociceptive responses by spinal mu opioid agonists: effects of stimulus intensity and agonist efficacy. Anesth Analg 1993;77(2):265-74
   PubMedGoogle Scholar
• Trujillo KA, Akil H. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science 1991;251(4989):85-7
   PubMedGoogle Scholar
• Marek P, Ben-Eliyahu S, Gold M, Liebeskind JC. Excitatory amino acid antagonists (kynurenic acid and MK-801) attenuate the development of morphine tolerance in the rat. Brain Res 1991;547(1):77-81
   PubMedGoogle Scholar
• Mao J. Opioid-induced abnormal pain sensitivity. Curr Pain Headache Rep 2006;10(1):67-70
   PubMedGoogle Scholar
• Mao J, Price DD, Mayer DJ. Mechanisms of hyperalgesia and morphine tolerance: a current view of their possible interactions. Pain 1995;62(3):259-74
   PubMedGoogle Scholar
• Gardell LR, Wang R, Burgess SE, Sustained morphine exposure induces a spinal dynorphin-dependent enhancement of excitatory transmitter release from primary afferent fibers. J Neurosci 2002;22(15):6747-55
   PubMedGoogle Scholar
• Vanderah TW, Suenaga NM, Ossipov MH, Tonic descending facilitation from the rostral ventromedial medulla mediates opioid-induced abnormal pain and antinociceptive tolerance. J Neurosci 2001;21(1):279-86
   PubMedGoogle Scholar
• King T, Ossipov MH, Vanderah TW, Is paradoxical pain induced by sustained opioid exposure an underlying mechanism of opioid antinociceptive tolerance? Neurosignals 2005;14(4):194-205
   PubMedGoogle Scholar
• Fishbain DA, Cole B, Lewis JE, Do opioids induce hyperalgesia in humans? An evidence-based structured review. Pain Med 2009;10(5):829-39
   PubMedGoogle Scholar
• Ho KY, Gan TJ, Habib AS. Gabapentin and postoperative pain – a systematic review of randomized controlled trials. Pain 2006;126(1-3):91-101
   PubMed Web of Science ®Google Scholar
• Drake R, Longworth J, Collins JJ. Opioid rotation in children with cancer. J Palliat Med 2004;7(3):419-22
   PubMedGoogle Scholar
• Indelicato RA, Portenoy RK. Opioid rotation in the management of refractory cancer pain. J Clin Oncol 2002;20(1):348-52
   PubMedGoogle Scholar
• Terner JM, Barrett AC, Lomas LM, Influence of low doses of naltrexone on morphine antinociception and morphine tolerance in male and female rats of four strains. Pain 2006;122(1-2):90-101
   PubMedGoogle Scholar
• Chindalore VL, Craven RA, Yu KP, Adding ultralow-dose naltrexone to oxycodone enhances and prolongs analgesia: a randomized, controlled trial of Oxytrex. J Pain 2005;6(6):392-9
   PubMedGoogle Scholar
• Davis AM, Inturrisi CE. d-Methadone blocks morphine tolerance and N-methyl-D-aspartate-induced hyperalgesia. J Pharmacol Exp Ther 1999;289(2):1048-53
   PubMedGoogle Scholar
• Eilers H, Philip LA, Bickler PE, The reversal of fentanyl-induced tolerance by administration of ‘small-dose’ ketamine. Anesth Analg 2001;93(1):213-14
   PubMedGoogle Scholar
• Silverman SM. Opioid induced hyperalgesia: clinical implications for the pain practitioner. Pain Physician 2009;12(3):679-84
   PubMedGoogle Scholar
• Noble M, Tregear SJ, Treadwell JR, Schoelles K. Long-term opioid therapy for chronic noncancer pain: a systematic review and meta-analysis of efficacy and safety. J Pain Symptom Manage 2008;35(2):214-28
   PubMedGoogle Scholar
• Moore RA, McQuay HJ. Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids. Arthritis Res Ther 2005;7(5):R1046-51
   Google Scholar
• Ballantyne JC, Mao J. Opioid therapy for chronic pain. N Engl J Med 2003;349(20):1943-53
   PubMedGoogle Scholar
• Eisenberg E, McNicol ED, Carr DB. Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: systematic review and meta-analysis of randomized controlled trials. JAMA 2005;293(24):3043-52
   PubMedGoogle Scholar
• Benyamin R, Trescot AM, Datta S, Opioid complications and side effects. Pain Physician 2008;11(2 Suppl):S105-20
   Google Scholar
• Stephanou A, Fitzharris P, Knight RA, Lightman SL. Characteristics and kinetics of proopiomelanocortin mRNA expression by human leucocytes. Brain Behav Immun 1991;5(4):319-27
   PubMedGoogle Scholar
• Peterson PK, Molitor TW, Chao CC. The opioid-cytokine connection. J Neuroimmunol 1998;83(1-2):63-9
   PubMedGoogle Scholar
• Rhodin A, Stridsberg M, Gordh T. Opioid endocrinopathy: a clinical problem in patients with chronic pain and long-term oral opioid treatment. Clin J Pain 2010;26(5):374-8078
   PubMedGoogle Scholar
• Sacerdote P, Bianchi M, Manfredi B, Panerai AE. Effects of tramadol on immune responses and nociceptive thresholds in mice. Pain 1997;72(3):325-30
   PubMedGoogle Scholar
• Manchikanti L. National drug control policy and prescription drug abuse: facts and fallacies. Pain Physician 2007;10(3):399-424
   PubMedGoogle Scholar
• Daniell HW. Opioid endocrinopathy in women consuming prescribed sustained-action opioids for control of nonmalignant pain. J Pain 2008;9(1):28-36
   PubMedGoogle Scholar
• Petraglia F, Porro C, Facchinetti F, Opioid control of LH secretion in humans: menstrual cycle, menopause and aging reduce effect of naloxone but not of morphine. Life Sci 1986;38(23):2103-10
   PubMedGoogle Scholar
• Swegle JM, Logemann C. Management of common opioid-induced adverse effects. Am Fam Physician 2006;74(8):1347-54
   PubMedGoogle Scholar
• Kurz A, Sessler DI. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs 2003;63(7):649-71
   PubMed Web of Science ®Google Scholar
• Yuan CS, Foss JF. Antagonism of gastrointestinal opioid effects. Reg Anesth Pain Med 2000;25(6):639-42
   PubMedGoogle Scholar
• Pappagallo M. Incidence, prevalence, and management of opioid bowel dysunction. Am J Surg 2001;182:11S-18S
   PubMed Web of Science ®Google Scholar
• Tassinari D, Sartori S, Tamburini E, Adverse effects of transdermal opiates treating moderate-severe cancer pain in comparison to long-acting morphine: a meta-analysis and systematic review of the literature. J Palliat Med 2008;11(3):492-501
   PubMedGoogle Scholar
• Leyendecker P, Hopp M, Bosse B, Bowel Function Index (BFI), a new validated questionaire for assessing opioid induced constipation. Proceeding of the 12th IASP World Congress on Pain; 17 – 22 August 2008; Glasgow, Scotland, UK
   Google Scholar
• Fishman J, Roffwarg H, Helman L. Disposition of naloxone-7,8-3H in normal and narcotic-dependent men. J Pharmacol Exp Ther 1973;187:575-80
   PubMed Web of Science ®Google Scholar
• Sykes NP. An investigation of the ability of oral naxolone to correct opioid-related constipation in patients with advanced cancer. Palliat Med 1006;10:135-44
   Google Scholar
• McNicol E, Boyce DB, Schumann R, Carr D. Efficacy and safety of mu-opioid antagonists in the treatment of opioid-induced bowel dysfunction: systemic review and meta-analysis of randomized controlled trials. Pain Med 2008;9:634-59
   PubMedGoogle Scholar
• McNicol ED, Boyce D, Schumann R, Carr DB. Mu-opioid antagonists for opioid-induced bowel dysfunction. Cochrane Database Syst Rev 2008;2:CD006332
   Google Scholar
• Ahmedzai S. New approaches to pain control in patients with cancer. Eur J Cancer 1997;33(Suppl 6):S8-14
   PubMedGoogle Scholar
• Koren G, Cairns J, Chitayat D, Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 2006;368(9536):704
   PubMedGoogle Scholar
• Pickworth WB, Neidert GL, Kay DC. Morphinelike arousal by methadone during sleep. Clin Pharmacol Ther 1981;30(6):796-804
   PubMedGoogle Scholar
• Slatkin N, Rhiner M. Treatment of opioid-induced delirium with acetylcholinesterase inhibitors: a case report. J Pain Symptom Manage 2004;27(3):268-73
   PubMedGoogle Scholar
• Ramaekers JG. Antidepressants and driver impairment: empirical evidence from a standard on-the-road test. J Clin Psychiatry 2003;64(1):20-9
   PubMedGoogle Scholar
• Byas-Smith MG, Chapman SL, Reed B, Cotsonis G. The effect of opioids on driving and psychomotor performance in patients with chronic pain. Clin J Pain 2005;21(4):345-52
   PubMedGoogle Scholar
• Budd RD, Muto JJ, Wong JK. Drugs of abuse found in fatally injured drivers in Los Angeles County. Drug Alcohol Depend 1989;23(2):153-8
   PubMedGoogle Scholar
• Haythornthwaite JA, Menefee LA, Quatrano-Piacentini AL, Pappagallo M. Outcome of chronic opioid therapy for non-cancer pain. J Pain Symptom Manage 1998;15(3):185-94
   PubMedGoogle Scholar
• Lyss AP, Portenoy RK. Strategies for limiting the side effects of cancer pain therapy. Semin Oncol 1997;24(5 Suppl 16): S16-28-34
   PubMedGoogle Scholar
• Mercadante S. Pathophysiology and treatment of opioid-related myoclonus in cancer patients. Pain 1998;74(1):5-9
   PubMedGoogle Scholar
• Han PK, Arnold R, Bond G, Myoclonus secondary to withdrawal from transdermal fentanyl: case report and literature review. J Pain Symptom Manage 2002;23(1):66-72
   PubMedGoogle Scholar
• Krantz MJ, Mehler PS. Synthetic opioids and QT prolongation. Arch Intern Med 2003;163(13):1615; author reply
   PubMedGoogle Scholar
• Walker PW, Klein D, Kasza L. High dose methadone and ventricular arrhythmias: a report of three cases. Pain 2003;103(3):321-4
   PubMedGoogle Scholar
• Katchman AN, McGroary KA, Kilborn MJ, Influence of opioid agonists on cardiac human ether-a-go-go-related gene K(+) currents. J Pharmacol Exp Ther 2002;303(2):688-94
   PubMedGoogle Scholar
• Sanguinetti MC, Jiang C, Curran ME, Keating MT. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 1995;81(2):299-307
   PubMed Web of Science ®Google Scholar
• Skjervold B, Bathen J, Spigset O. Methadone and the QT interval: relations to the serum concentrations of methadone and its enantiomers (R)-methadone and (S)-methadone. J Clin Psychopharmacol 2006;26(6):687-9
   PubMedGoogle Scholar
• Pearson EC, Woosley RL. QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system. Pharmacoepidemiol Drug Saf 2005;14(11):747-53
   PubMedGoogle Scholar
• Cardiac Vigilance Recommended for Methadone. 2005. Available from: http://www.medsafe.govt.nz/profs/puarticles/methadone.htm [Cited]
   Google Scholar
• International Classification of Disease (ICD-10). 2007. Available from: http://www.who.int/classifications/icd/en [Cited April 2010]
   Google Scholar
• Savage SR, Joranson DE, Covington EC, Definitions related to the medical use of opioids: evolution towards universal agreement. J Pain Symptom Manage 2003;26(1):655-67
   PubMedGoogle Scholar
• Holding MY, Saulino MF, Overton EA, Interventions in chronic pain management. 1. Update on important definitions in pain management. Arch Phys Med Rehabil 2008;89(3 Suppl 1):S38-40
   Google Scholar
• Michna E, Ross EL, Hynes WL, Predicting aberrant drug behavior in patients treated for chronic pain: importance of abuse history. J Pain Symptom Manage 2004;28(3):250-8
   PubMedGoogle Scholar
• Reid MC, Engles-Horton LL, Weber MB, Use of opioid medications for chronic noncancer pain syndromes in primary care. J Gen Intern Med 2002;17(3):173-9
   PubMedGoogle Scholar
• Ives TJ, Chelminski PR, Hammett-Stabler CA, Predictors of opioid misuse in patients with chronic pain: a prospective cohort study. BMC Health Serv Res 2006;6:46
   PubMed Web of Science ®Google Scholar
• Edlund MJ, Steffick D, Hudson T, Risk factors for clinically recognized opioid abuse and dependence among veterans using opioids for chronic non-cancer pain. Pain 2007;129(3):355-62
   PubMedGoogle Scholar
• Hojsted J, Sjogren P. Addiction to opioids in chronic pain patients: a literature review. Eur J Pain 2007;11(5):490-518
   PubMedGoogle Scholar
• Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. Pain Med 2005;6(6):432-42
   PubMedGoogle Scholar
• Passik SD, Kirsh KL, Casper D. Addition-related assessment tools and pain management: instruments for screening, treatment planning, and monitoring compliance. Pain Med 2008;9(S2):S145-66
   Google Scholar
• Chou R, Fanciullo GJ, Fine PG, Opioids for chronic noncancer pain: prediction and identification of aberrant drug-related behaviors: a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain 2009;10(2):131-46
   PubMedGoogle Scholar
• Passik SD, Kirsh KL, Whitcomb L, A new tool to assess and document pain outcomes in chronic pain patients receiving opioid therapy. Clin Ther 2004;26(4):552-61
   PubMedGoogle Scholar
• Butler SF, Budman SH, Fernandez KC, Development and validation of the current opioid misuse measure. Pain 2007;130(1-2):144-56
   PubMedGoogle Scholar
• Katz N, Fanciullo GJ. Role of urine toxicology testing in the management of chronic opioid therapy. Clin J Pain 2002;18(4 Suppl):S76-82
   Google Scholar
• Manchikanti L, Atluri S, Trescot AM, Giordano J. Monitoring opioid adherence in chronic pain patients: tools, techniques, and utility. Pain Physician 2008;11(2 Suppl):S155-80
   Google Scholar
• Arnold RM, Han PK, Seltzer D. Opioid contracts in chronic nonmalignant pain management: objectives and uncertainties. Am J Med 2006;119(4):292-6
   PubMedGoogle Scholar
• Fishman SM, Bandman TB, Edwards A, Borsook D. The opioid contract in the management of chronic pain. J Pain Symptom Manage 1999;18(1):27-37
   PubMedGoogle Scholar
• Fishman SM, Kreis PG. The opioid contract. Clin J Pain 2002;18(4 Suppl):S70-5
   Google Scholar
• Burchman SL, Pagel PS. Implementation of a formal treatment agreement for outpatient management of chronic nonmalignant pain with opioid analgesics. J Pain Symptom Manage 1995;10(7):556-63
   PubMedGoogle Scholar
• Collen M. Opioid contracts and random drug testing for people with chronic pain – think twice. J Law Med Ethics 2009;37(4):841-5
   PubMedGoogle Scholar
• Yudko E, Lozhkina O, Fouts A. A comprehensive review of the psychometric properties of the drug abuse screening test. J Subst Abuse Treat 2007;32(2):189-98
   PubMedGoogle Scholar
• Akbik H, Butler SF, Budman SH, Validation and clinical application of the Screener and Opioid Assessment for Patients with Pain (SOAPP). J Pain Symptom Manage 2006;32(3):287-93
   PubMedGoogle Scholar
• Butler SF, Fernandez K, Benoit C, Validation of the revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R). J Pain 2008;9(4):360-72
   PubMedGoogle Scholar
• Butler SF, Budman SH, Fernandez K, Jamison RN. Validation of a screener and opioid assessment measure for patients with chronic pain. Pain 2004;112(1-2):65-75
   PubMedGoogle Scholar
• Belgrade MJ, Schamber CD, Lindgren BR. The DIRE score: predicting outcomes of opioid prescribing for chronic pain. J Pain 2006;7(9):671-81
   PubMedGoogle Scholar